sponsored
PatientsVille.com Logo

PatientsVille

Pemetrexed Medical Research Studies

Up-to-date List of Pemetrexed Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pemetrexed Medical Research Studies

Rank Status Study
1 Not yet recruiting Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
Conditions: Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: crizotinib;   Drug: Pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: PFS between patients randomized to receive Pemetrexed disodium monotherapy versus crizotinib and Pemetrexed disodium combination therapy;   Incidence of adverse events of crizotinib in combination with Pemetrexed disodium, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Response rate (confirmed and unconfirmed) with Pemetrexed disodium monotherapy;   Response rates (confirmed and unconfirmed) of crizotinib with Pemetrexed disodium;   Patterns of failure;   Overall survival
2 Recruiting Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Crizotinib (Xalkori);   Drug: Pazopanib;   Drug: Pemetrexed
Outcome Measure: Maximum Tolerated Dose (MTD)
3 Unknown  Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Pemetrexed plus carboplatin
Outcome Measures: To compare time to progression between the combination Pemetrexed-carboplatin and Pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC;   To assess differences in terms of response rate between the combination Pemetrexed-carboplatin and Pemetrexed alone.;   To assess differences in terms of duration of response between the combination Pemetrexed-carboplatin and Pemetrexed alone.;   To assess differences in terms of toxicity between the combination Pemetrexed-carboplatin and Pemetrexed alone.;   To assess differences in terms of survival between the combination Pemetrexed-carboplatin and Pemetrexed alone.
4 Recruiting Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy
Condition: Carcinoma, Non-small-cell Lung
Interventions: Drug: maintenance Pemetrexed;   Drug: Pemetrexed at progression
Outcome Measures: overall survival;   progression free survival;   Toxicity;   Health related quality of life
5 Recruiting Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: TH-302 combination with Pemetrexed;   Drug: Matched placebo in combination with Pemetrexed
Outcome Measures: Overall survival;   Incidence and severity of adverse events in patients treated with TH-302 in combination with Pemetrexed vs Pemetrexed alone;   Population PK of TH-302 in patients treated with TH-302 for measures including clearance and volume of distribution;   Evaluate anti-tumor activity as measured by progression-free survival and response rate in patients treated with TH-302 in combination with pemtrexed vs Pemetrexed alone
6 Recruiting Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Condition: Central Nervous System Lymphoma
Intervention: Drug: Pemetrexed
Outcome Measures: To assess the safety and to determine the maximum tolerated dose of Pemetrexed given intravenously for the treatment of recurrent lymphoma invading the CNS.;   To determine the plasma pharmacokinetics of Pemetrexed and assess drug penetration into the CSF.;   To provide preliminary evidence of Pemetrexed activity against brain lymphoma my MRI criteria of clearance of CSF lymphoma cells.;   To identify the time to complete response.;   To provide a measure of reduction of enhancing tumor volume as compared to our nomogram of reduction of tumor volume for methotrexate recipients with brain lymphoma.
7 Recruiting Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Pemetrexed/Oxaliplatin
Outcome Measures: To determine the clinical feasibility rate (CFR) of 4 cycles of adjuvant chemotherapy with Pemetrexed followed by Pemetrexed/oxaliplatin in patients with NSCLC stage IB, IIA, IIB and IIIA after a postsurgical interval of 2-4 weeks.;   To determine the time to treatment failure, the relapse free survival, the overall survival, the distant metastases free survival, local relapse free survival, the localization of relapse.
8 Recruiting Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LBH 589;   Drug: Pemetrexed
Outcome Measures: To determine the maximum tolerated dose of LBH589 given on a three times weekly schedule when combined with Pemetrexed for the treatment of patients with advanced thoracic malignancies, except squamous cell carcinoma of the lung (phase I part);   Determine the overall response rate and non-progression rate (clinical benefit rate) and progression-free survival of the combination of LBH589 and Pemetrexed in patients with previously-treated advanced NSCLC (phase II part).;   Determine the pharmacodynamic effects of LBH589 and Pemetrexed on levels of HDAC 1 and 6 in peripheral blood mononuclear cells, as well as on levels of VEGF levels in the blood.;   Identify biomarkers in baseline, archival tumor tissue that may correlate with antitumor efficacy.
9 Unknown  Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Pemetrexed and erlotinib
Outcome Measures: Progression-free survival;   Objective response rate;   Disease control rate;   Safety profile of Pemetrexed and erlotinib combination;   Assessment of molecular markers for biologic effects and predictive response
10 Recruiting Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Ruxolitinib;   Drug: Placebo;   Drug: Pemetrexed;   Drug: Cisplatin
Outcome Measures: Part 1: Determination of the dose of ruxolitinib that is safe and tolerable in combination with Pemetrexed/cisplatin as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.;   Part 2: Overall Survival (OS);   Progression-free survival (PFS);   Objective Response Rate;   Duration of Response;   Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.
11 Recruiting Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Dacomitinib, Pemetrexed
Outcome Measures: Maximal tolerated dose;   MULTIPLE measures - this outcome is a composite !!
12 Recruiting Modufolin (6R 5,10-Methylenetetrahydrofolate) and Pemetrexed for Neoadjuvant Rectal Cancer Treatment
Condition: Rectal Cancer
Interventions: Drug: [6R] 5,10-methylenetetrahydrofolate;   Drug: Pemetrexed
Outcome Measures: Feasibility of Pemetrexed Prior to Surgery;   Pathological Complete Response (pCR);   Number of Participants Receiving Sphincter Saving Surgery;   Evaluation of qualitative and quantitative toxicities;   [6R] 5,10-methylenetetrahydrofolate tissue concentration determination;   Correlation between 5,10-methylenetetrahydrofolate and HCy levels in blood;   Correlation of folate gene polymorphisms and gene signature profiling with clinical outcome and toxicity profiles.;   Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma
13 Recruiting PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: PI3K inhibitor BKM120;   Drug: Pemetrexed disodium;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: quality-of-life assessment
Outcome Measures: Maximum tolerated dose, defined as the highest dose in which fewer than 33% of study participants experience a dose limiting toxicity (DLT), graded according to the National Cancer Institute (NCI) CTCAE version 4.0;   Toxicity profile of PI3K inhibitor BKM120, assessed using NCI CTCAE version 4.0;   Pharmacokinetic (PK) parameters of PI3K inhibitor BKM120, carboplatin, and Pemetrexed disodium in combination;   Anti-tumor activity (complete response [CR] + partial response [PR]), assessed using RECIST;   Disease control rate (CR + PR + stable disease [SD]), assessed using RECIST;   Progression free survival;   Overall survival
14 Recruiting Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Conditions: Solid Tumors;   Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Panobinostat, Cisplatin, Pemetrexed
Outcome Measures: Safety and feasibility of oral panobinostat in combination with cisplatin and Pemetrexed;   Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0;   Dose-limiting toxicities and toxicity profile as assessed by NCI CTCAE, Version 4.0;   Exploratory biomarker analysis;   Efficacy of oral panobinostat in combination with cisplatin/Pemetrexed in an expanded cohort of patients with NSCLC
15 Recruiting Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
Condition: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: exemestane;   Drug: Pemetrexed disodium;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Outcome Measures: Tabulation, grading, and attribution of serious adverse events (SAEs) and adverse events (AEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0;   Proportion achieving clinical response;   Quality of life in patients treated with Pemetrexed disodium, carboplatin and exemestane
16 Recruiting Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC
Condition: NSCLC
Interventions: Drug: Cisplatinum;   Drug: Pemetrexed
Outcome Measure: Response rate
17 Recruiting Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor
Interventions: Drug: sorafenib tosylate;   Drug: Pemetrexed disodium;   Other: laboratory biomarker analysis;   Procedure: biopsy
Outcome Measures: Recommended phase 2 doses for the combination of Pemetrexed disodium with sorafenib tosylate;   Number of subjects in whom study treatment produces antitumor effects of the combination;   Number of biopsy specimens that successfully stain for Beclin1;   Number of biopsy specimens that can be analyzed for PDGFRb expression;   Analysis of pTEN expression in biopsy specimens
18 Unknown  Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Carboplatin;   Drug: Pemetrexed
Outcome Measures: To evaluate the response rate of combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in recurrent ovarian, primary peritoneal, and fallopian tube carcinoma.;   To evaluate the progression free interval, overall survival, and adverse effects among patients receiving this drug combination.
19 Recruiting Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: PemCarbo;   Drug: Pem only
Outcome Measures: Progression free survival;   Objective response rate, Overall survival, Safety and Quality of life
20 Recruiting Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Condition: Lung Cancer
Interventions: Biological: bevacizumab, erlotinib;   Drug: bevacizumab, Pemetrexed, cisplatin
Outcome Measures: Progression-free survival at 6 months in stratum wtEGFR cohort 1;   Progression-free survival;   Overall survival;   Best response (RECIST 1.1);   Adverse events (CTCAE v4.0);   Molecular markers in tumor tissue and blood

These studies may lead to new treatments and are adding insight into Pemetrexed etiology and treatment.

A major focus of Pemetrexed research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Pemetrexed